Heavy Metal Or Aluminum Containing Patents (Class 552/504)
  • Patent number: 10316055
    Abstract: The present invention relates to a method of purification of compound of formula (I) which comprises the step of crystallization of compound of formula (I) from a composition comprising the compound of formula (I) and the compound of formula (II) and a specific solvent system containing ethanol, 1-propanol, 2-propanol, 2-methyl-1-propanol, 1-butanol or 2-butanol.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: June 11, 2019
    Assignee: DSM IP ASSETS B.V.
    Inventors: Jan Schuetz, Ralph Waechter
  • Patent number: 9802977
    Abstract: The present invention discloses a method for synthesizing 25-hydroxy cholesterol. The method is as below: subjecting 24-dehydrocholesterol derivative as a raw material, which undergoes an addition reaction with a hydroxyl containing reagent in an organic solvent under catalysis, and then hydrolyzing the reaction product and separating to obtain 25-hydroxy cholesterol. The present invention adopts hydroxyl containing reagents such as water, formic acid, acetic acid, propionic acid, butyric acid, benzoic acid, p-methyl benzoic acid to replace the commonly used extremely toxic reagents such as Cr reagent, Hg reagent and polyfluorinated acetone in the prior art. The raw materials of the present invention are easily available, and have low effect on environment. The operation and post treatment are convenient.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: October 31, 2017
    Inventors: Can Jin, Weike Su, Ziqiang Wang, Jiangang Liu, Bin Sun, Wenhao Xu
  • Publication number: 20140274936
    Abstract: A coordination complex having a physiologically acceptable pKa includes a metal and a biologically active agent. The pKa of the coordination complex is less than the pKa of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.
    Type: Application
    Filed: May 29, 2014
    Publication date: September 18, 2014
    Applicant: SYNTHONICS, INC.
    Inventors: Thomas Piccariello, John D. Price, Robert A. Oberlender, Michaela E. Mulhare, Mary C. Spencer, Scott B. Palmer
  • Publication number: 20140046021
    Abstract: The molecular structures of metal-salen complexes which exerts pharmacological effects are clarified and the metal-salen complexes having such molecular structures and their derivatives are provided. A metal-salen complex compound is characterized in that a metal atom part in each of multiple molecules of the metal-salen complex or its derivative is multimerized via water.
    Type: Application
    Filed: January 19, 2012
    Publication date: February 13, 2014
    Applicants: IHI CORPORATION
    Inventors: Yoshihiro Ishikawa, Haruki Eguchi
  • Publication number: 20130052131
    Abstract: Embodiments of the present disclosure, in one aspect, relate to a nanoparticle, methods of imaging a tumor, method of imaging a disease, method of treating a condition, disease, or related biological event, or the like.
    Type: Application
    Filed: August 24, 2012
    Publication date: February 28, 2013
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Zhen Cheng, Kai Cheng
  • Publication number: 20120189571
    Abstract: The invention is directed to biocompatible conjugated polymer nanoparticles including a copolymer backbone, a plurality of sidechains covalently linked to said backbone, and a plurality of platinum compounds dissociably linked to said backbone. The invention is also directed to dicarbonyl-lipid compounds wherein a platinum compound is dissociably linked to the dicarbonyl compound. The invention is also directed to methods of treating cancer or metastasis. The methods includes selecting a subject in need of treatment for cancer or metastasis and administering to the subject an effective amount of any of the nanoparticles, compounds, or compositions of the invention.
    Type: Application
    Filed: February 4, 2010
    Publication date: July 26, 2012
    Inventors: Shiladitya Sengupta, Abhimanyu Paraskar, Shivani Soni, Sudipta Basu, Poulomi Sengupta
  • Publication number: 20120029167
    Abstract: A drug using the magnetic properties of a metal salen complex as represented by the following general formula in order to magnetize the intended drug by chemically binding the drug to a metal salen complex so that the drug can be delivered to the target diseased site. The drug can be delivered to the diseased site using the magnetic properties of the drug per se without using a carrier made of a magnetic substance as in the conventional methods.
    Type: Application
    Filed: May 20, 2011
    Publication date: February 2, 2012
    Applicants: Yoshihiro Ishikawa, IHI Corporation
    Inventors: Yoshihiro ISHIKAWA, Haruki Eguchi
  • Publication number: 20100160268
    Abstract: A pharmacologic agent for treating and/or preventing cancer, among other diseases and conditions, and particularly breast, prostate, and pancreatic cancer, in humans and animals. The novel pharmacologic agent is an isoflavonoid or isoflavonoid mimetic covalently attached to a cytotoxic pharmacophore that, preferably has the ability to conjugate with a metal salt to form a more potent metal complex, particularly a Cu(II) complex. The isoflavonoid or isoflavonoid mimetic may he non-fragmented steroidal hormone, such as progesterone which is structurally related to the isoflavone genistein, or a small molecule hormone mimetic, such as chromone. An illustrative non-fragmented steroidal embodiment is 17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,13,14,15, 16,17-tetradecahydrocyclopenta[a]phenanthren-3-thiosemicarbazone and its Cu(II) complex. Effective chromone analogs include the thiosemicarbazone and hydrazone analogs of 4-oxo-4H-chromene-3-carboxaldehyde and their Cu(IT) complexes.
    Type: Application
    Filed: September 25, 2006
    Publication date: June 24, 2010
    Inventors: Sarkar Fazlul, Subhash Padhye
  • Publication number: 20090169484
    Abstract: The present invention provides a drug delivery system that overcomes conventional technical problems and that is readily put to practical use. Iron-salen complexes represented by General Formula (I) below. The invention renders iron-salen complexes magnetic, which can thus be used as drugs that can be delivered to affected areas in the body using the inherent magnetic properties of the drug without employing carriers composed of magnetic substances as has been done hitherto.
    Type: Application
    Filed: June 26, 2008
    Publication date: July 2, 2009
    Applicants: IHI Corporation, Yoshihiro Ishikawa
    Inventors: Haruki Eguchi, Yoshihiro Ishikawa
  • Publication number: 20040235712
    Abstract: In part, the present invention is directed to coordination complexes comprising a therapeutic agent. In one aspect, the subject compositions comprise a platinum metal center and a covalently attached therapeutic agent.
    Type: Application
    Filed: January 12, 2004
    Publication date: November 25, 2004
    Inventors: Stephen J. Lippard, Carmen M. Barnes, Ariel Haskel, Katie R. Barnes
  • Patent number: 6737417
    Abstract: The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): in which R1 represents a hydrogen atom, etc., R2 represents a C1-C7 halogenoalkyl group, etc., m represents an integer of 2 to 14, and n represents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: May 18, 2004
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: JaeChon Jo, HeeAn Kwon, HyunSuk Lim, JaeYoung Choi, Kazumi Morikawa, Yoshitake Kanbe, Masahiro Nishimoto, MyungHwa Kim, Yoshikazu Nishimura
  • Patent number: 6720307
    Abstract: Novel analogs of fusidic acid are described with one or more carbohydrate units attached. Certain glycosylated analogs of fusidic acid have enhanced solubility properties in diluents or excipient of choice as compared to unmodified fusidic acid. Certain glycosylated analogs may be employed as chemotherapeutic agents and particular analogs may be useful for fighting anti-microbial infections.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: April 13, 2004
    Assignee: The University of Michigan
    Inventors: Roeland Tuinman, Masato Koreeda, Brian Keith Shull
  • Publication number: 20040034216
    Abstract: A compound of formula (I) and pharmaceutical acceptable salts, solvates, stereoisomers and prodrugs thereof, in isolation or in mixture, wherein, independently at each occurrence: R1 and R2 are selected from hydrogen, oxygen so as to form nitro or oxime, amino, sulfate, and sulfonic acid, and organic groups having 1-30 carbons and optionally containing 1-6 heteroatoms selected from nitrogen, oxygen, phosphorous, silicon, and sulfur, where R1 and R2 may, together with the N to which they are both bonded, form a heterocyclic structure that may be part of an organic group having 1-30 carbons and optionally containing 1-6 heteroatoms selected from nitrogen, oxygen and silicon, and where R1 may be a 2, or 3 atom chain to numeral 2 so that —N—R1— forms part of a fused bicyclic structure to ring A; R3 and R4 are selected from direct bonds to 6 and 7 respectively so as to form carbonyl groups, hydrogen, or a protecting group such that R3 and/or R4 is part of hydroxyl or carbonyl protecting group; nu
    Type: Application
    Filed: March 13, 2003
    Publication date: February 19, 2004
    Inventors: Jeffrey R. Raymond, Claudia E. Kasserra, Yaping Shen
  • Publication number: 20040006051
    Abstract: 1
    Type: Application
    Filed: March 27, 2003
    Publication date: January 8, 2004
    Applicant: Gervais Berube
    Inventor: Gervais Berube
  • Publication number: 20030220311
    Abstract: The compositions and methods disclosed herein provide heterobifunctional programmable genotoxic compounds that can be designed to kill selected cells present in a heterogenous cell population. The present compounds comprise a first agent that inflicts damage on cellular DNA, and a second agent that attracts a macromolecular cell component such as a protein, which in turn shields genomic lesions from repair. Unrepaired lesions therefore persist in the cellular genome and contribute to the death of selected cells. In contrast, lesions formed in nonselected cells, which lack the cell component, are unshielded and thus are repaired. As a result, compounds described herein are less toxic to nonselected cells. Compounds of this invention can be designed to cause the selective killing of transformed cells, viral-infected cells and the like.
    Type: Application
    Filed: November 18, 2002
    Publication date: November 27, 2003
    Inventors: John M. Essigmann, Robert G. Croy, Kevin J. Yarema, Marshall Morningstar
  • Publication number: 20030113265
    Abstract: Compounds able to chelate paramagnetic metal ions and the use thereof as contrast agents in the technique known as “Magnetic Resonance Imaging” (M.R.I.), which consist of at least two chelating agents conjugated via a multivalent linker group, to a bile acid.
    Type: Application
    Filed: August 27, 2002
    Publication date: June 19, 2003
    Inventors: Christoph De Haen, Andrea Beltrami, Enrico Cappelletti, Luciano Lattuada, Mario Virtuani
  • Publication number: 20010056074
    Abstract: The invention consists of a compound of the general formula (I) below: 1
    Type: Application
    Filed: January 4, 2001
    Publication date: December 27, 2001
    Inventors: Jean-Jacques Yaouanc, Erwann Guenin, Jean-Claude Clement, Anne-Cecile Herve, Claude Ferec, Virginie Floch, Herve des Abbayes
  • Patent number: 5585468
    Abstract: This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, substantial thioureas for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.
    Type: Grant
    Filed: June 27, 1994
    Date of Patent: December 17, 1996
    Assignee: Cytogen Corporation
    Inventors: Daniel J. Coughlin, Benjamin A. Belinka, Jr.
  • Patent number: 5326856
    Abstract: This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, isothiocyanate derived thiocarbonyls for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.
    Type: Grant
    Filed: April 9, 1992
    Date of Patent: July 5, 1994
    Assignee: Cytogen Corporation
    Inventors: Daniel J. Coughlin, Benjamin A. Belinka, Jr.
  • Patent number: 5273971
    Abstract: There are provided 13-alkyl-11beta-phenyl-gonanes of formula I ##STR1## wherein Z is an oxygen atom or N--OH;R.sup.2 is alpha- or beta-position methyl or ethyl;R.sup.1 is selected from heteroaryl radicals, cycloalkyl radicals, cycloalkenyl radicals, aryl radicals, alkenyl radicals, and alkyl radicals where R.sup.2 is in the alpha-position and an ethyl radical where R.sup.2 is in the beta-position; andR.sup.3 and R.sup.4 are selected from one of two different groups of substituent pairs, the group from which the selection is made being determined by the position of R.sup.2.
    Type: Grant
    Filed: July 3, 1989
    Date of Patent: December 28, 1993
    Assignee: Schering Aktiengesellschaft
    Inventors: Stefan Scholz, Eckhard Ottow, Guenter Neef, Walter Elger, Sybille Beier, Krzysztof Chwalisz
  • Patent number: 5232915
    Abstract: 9.alpha.-Hydroxy-19,11.beta.-bridged steroids of general formula I ##STR1## are described. The more detailed meaning of A, B, R.sup.1, R.sup.2, G, Z, R.sup.4 --Y and R.sup.4' --Y' follows from the description. The steroids of general formula I have antigestagen and/or antiglucocorticoidal action and can be used for the production of pharmaceutical agents.
    Type: Grant
    Filed: January 14, 1992
    Date of Patent: August 3, 1993
    Assignee: Schering Aktiengesellschaft
    Inventors: Eckhard Ottow, Gunter Neef, Rudolf Wiechert, Walter Elger, Sybille Beier, Karl-Heinrich Fritzemeier
  • Patent number: 4975536
    Abstract: The present invention is a process for conversion of .DELTA..sup.16 -steroids (I) ##STR1## to the corresponding .DELTA..sup.17(20) -20-silyl ether (III) ##STR2## by reaction with (1) a preformed copper hydride or a metal hydride reducing agent in the presence of a copper species and (2) a silylating agent. The .DELTA..sup.17(20) -20-silyl ether (III) are useful intermediates in the preparation of steroids useful as pharmaceuticals.
    Type: Grant
    Filed: June 2, 1989
    Date of Patent: December 4, 1990
    Assignee: The Upjohn Company
    Inventor: Kenneth P. Shephard
  • Patent number: 4945064
    Abstract: Estrane and androstane derivatives of formula I ##STR1## wherein X is bromine, iodine, triphenyltin or trialkyltin of 1 to 6 carbon atoms per alkyl radical,Y represents two hydrogen atoms or methylene,Z represents two hydrogen atoms, oxo or alkylenedioxy of 2 to 6 carbon atoms andV is ethylene, vinylene, 1,3-propylene or cyclopropylene,R.sub.1 is hydrogen or a hydrocarbon radical of up to 8 hydrocarbon atoms, optionally interrupted by an oxa group or substituted by an oxo group,R.sub.2 is methyl or ethyl,R.sub.3 and R.sub.4 represent a carbon-carbon bond or R.sub.3 is hydrogen and R.sub.4 is hydrogen or methyl,.DELTA.symbolizes a 4(5)-double bond if Z signifies two hydrogen atoms or an oxo group; or a 5(6)-double bond or, for the estrane derivatives of formula I, also a 5(10)-double bond, if Z is alkylenedioxy,are pharmacologically effective substances or intermediates for preparation thereof.
    Type: Grant
    Filed: January 19, 1988
    Date of Patent: July 31, 1990
    Assignee: Schering Aktiengesellschaft
    Inventors: Helmut Hofmeister, Henry Laurent, Paul E. Schulze, Klaus Annen, Rudolf Wiechert, Kunhard Pollow, Bernhard Manz, Hans-Joerg Grill
  • Patent number: 4937262
    Abstract: Derivatives of platinum group metals, particularly platinum itself, wherein the metal is linked to one or more pharmaceutically acceptable steroid, fatty acid or other lipophilic residues aiding transport of the metal across cell membranes in the body, particularly fatty acid amine or fatty acid amide groups ##STR1## where R is a hydrocarbon group, suitably of 10 to 30 carbon atoms. The derivatives are useful in the treatment of cancer.
    Type: Grant
    Filed: August 24, 1987
    Date of Patent: June 26, 1990
    Assignee: EFAMOL Ltd.
    Inventor: Bruce C. Davidson